GlobalData on MSN5d
Pfizer settles Biohaven kickback claims case for $59.7mBiohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaurants and paid speaker honoraria for ...
Pfizer’s subsidiary Biohaven has agreed to a settlement nearing $60 million to resolve allegations of false claims related to ...
Over the years, the U.S. Department of Justice (DOJ) has taken a host of drugmakers to task over alleged kickback payments ...
Biohaven wielded meals at high-end restaurants and paid speaking opportunities to induce healthcare providers to prescribe ...
The alleged violations occurred before Pfizer bought Biohaven and its migraine treatment three years ago for $11.6 billion.
Pfizer (PFE) has agreed to pay nearly $60M to resolve allegations that its Biohaven unit paid kickbacks to induce ...
Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary ...
Shares of Biohaven Ltd. (NYSE:BHVN – Get Free Report) have been assigned a consensus rating of “Buy” from the fourteen analysts that are presently covering the company, MarketBeat.com reports.
In another cautionary tale of kicking all the tires before an acquisition, Pfizer Inc. agreed to a nearly $60 million settlement to resolve a whistleblower’s claims that Biohaven Pharmaceutical ...
The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback